In this case Study (Fat Diet NASH Mouse model N=4, vs Drug A and Drug B candidates, N=4) we highlight the combined efficacy of the drug candidates as anti-steatotic and and-fibrotic compounds. Dots are the group averages. Our method uses ONE FFPE slide to derive all the information. Turnaround time is les than 2 weeks for a typical 4 arms x 4 animals study.
Fibrosis Phenotyping establishes pre-clinical continuous scores to assess the severity and progression of fibrosis.
Fibrosis Phenotyping establishes clinical continuous scores to assess the severity and progression of fibrosis.
Continuous Scores can show the real effect of a compound
As opposed to Categorical Scores, Fibrosis Continuous scores can reveal the real benefit of a therapeutic Compound (as illustrated below, in Red: A patient moving from F1+ to F1- is not identified to from the treatment using categorical scores (left figure), while continuous score show it (right figure).
Early result support the hypothesis that there are multiple forms of fibrosis and that the related fibrosis phenotypes are very heterogeneous. The case study (below) shows that FibroNest can help classify pediatric patients with NASH-1 and NASH-2 forms, two well described forms of NASH. Further validation studies are on-going. We welcome investigator initiated study proposals in this field.